Last reviewed · How we verify

Macrilen — Competitive Intelligence Brief

Macrilen (MACIMORELIN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth Hormone Secretagogue Receptor Agonist. Area: Other.

marketed Growth Hormone Secretagogue Receptor Agonist Growth hormone secretagogue receptor type 1 Other Small molecule Live · refreshed every 30 min

Target snapshot

Macrilen (MACIMORELIN) — Aeterna Zentaris. Macrilen works by binding to the growth hormone secretagogue receptor type 1, triggering a response that stimulates the release of growth hormone.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Macrilen TARGET MACIMORELIN Aeterna Zentaris marketed Growth Hormone Secretagogue Receptor Agonist Growth hormone secretagogue receptor type 1 2017-01-01
Capimorelin CAPROMORELIN marketed Growth hormone secretagogue receptor type 1, Growth hormone secretagogue receptor type 1
Adlumiz ANAMORELIN ONO PHARMACEUTICAL Co., Ltd marketed Growth hormone secretagogue receptor type 1
MACIMORELIN ACETATE MACIMORELIN ACETATE marketed Growth Hormone Secretagogue Receptor Agonist [EPC] 2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth Hormone Secretagogue Receptor Agonist class)

  1. Aeterna Zentaris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Macrilen — Competitive Intelligence Brief. https://druglandscape.com/ci/macimorelin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: